New York, NY—July 28, 2025 — FEMSelect, an innovative leader in women’s healthcare, is committed to improving women’s quality of life by breaking the stigma around a widespread condition that impacts millions. Although it is estimated that 50% of women will experience some degree of pelvic organ prolapse, many suffer in silence and delay seeking treatment due to the lack of information and stigma surrounding this condition.
Pelvic organ prolapse occurs when the pelvic floor muscles are weakened or damaged, making them unable to support the organs and maintain proper tissue placement. This can result in significant discomfort, pain during sex, urinary incontinence, and a decline in overall well-being.
FEMSelect has launched EnPlace, an FDA-cleared minimally-invasive, same-day approach to pelvic organ prolapse repair that requires no hospital stay. Patients can resume normal activities within several days, there is no scarring, and the uterus is preserved. This revolutionary device addresses a pressing need for effective solutions in the management of pelvic pain and related conditions, enhancing the quality of life for women worldwide.
Since EnPlace was introduced, more than 4,000 successful procedures have been performed to date. Although headquartered in New York, the company operates worldwide—including in Israel, Latin America, and Cyprus—and is preparing to expand into Europe soon.
Starting July 1, 2025, FEMSelect secured a national group purchasing agreement with Premier, Inc. Premier is a prominent healthcare improvement company powered by technology, serving approximately two-thirds of all healthcare providers in the United States. As a key player in the dynamic healthcare landscape, Premier connects providers, suppliers, payers, and policymakers to enhance healthcare on a national scale—making it smarter through data-driven insights and faster through innovative technologies. Together, FEMSelect and Premier members can provide EnPlace as a minimally invasive, transformative option for women looking for relief from this widespread condition.
“We are dedicated to advancing women’s healthcare by delivering innovative solutions that empower women to lead confident, comfortable lives,” said Sasha Schrode, CEO, FEMSelect. “With EnPlace, we’re not just helping to treat pelvic organ prolapse—we’re also empowering women to advocate for their health and highlighting the need for and increasing availability of accessible, comprehensive healthcare options.”
“Traditional surgical methods can often be invasive, leading to longer recovery times and increased risks of complications,” said Debbie Garner, President, FEMSelect. “With EnPlace, we are representing a significant advancement in treatment, providing women with a short recovery and quick return to activities with a minimally invasive approach.”
FEMSelect is dedicated to ongoing research and development in women’s health, ensuring that the latest advancements are not only effective but also accessible.
About FEMSelect:
FEMSelect is an innovative leader in women’s healthcare, dedicated to developing advanced solutions for common conditions affecting women’s health. By focusing on innovative, patient-centered approaches, FEMSelect aims to improve treatment outcomes and enhance the quality of life for women.
Media Requests:
Stefanie Williamson
631.754.0460
